AKT1 and colitis: In the same context, the inhibition of the mammalian target of rapamycin (mTOR), a downstream molecule of PI3K/AKT pathway, has also been proven to afford significant anti-inflammatory actions against colitis progression through dampening the T-cell function and NF-κB activation.